Regenxbio (RGNX) Change in Account Payables (2014 - 2025)

Regenxbio's Change in Account Payables history runs 12 years deep, the most recent figure standing at -$1.9 million for Q4 2025.

• On a quarterly basis, Change in Account Payables fell 161.26% year-over-year to -$1.9 million in Q4 2025; TTM through Dec 2025 was -$2.3 million, a 682.19% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 million, down 682.19% from the prior year.
• Change in Account Payables eased to -$1.9 million in Q4 2025 per RGNX's latest filing, from $694000.0 in the prior quarter.
• Across five years, Change in Account Payables topped out at $16.8 million in Q1 2022 and bottomed at -$14.9 million in Q2 2024.
• The 5-year median for Change in Account Payables is $957000.0 (2023), against an average of $555950.0.
• Biggest YoY gain for Change in Account Payables was 5926.98% in 2022; the steepest drop was 542.49% in 2022.
• Year by year, Change in Account Payables stood at -$8.8 million in 2021, then soared by 121.65% to $1.9 million in 2022, then sank by 36.03% to $1.2 million in 2023, then jumped by 149.02% to $3.0 million in 2024, then tumbled by 161.26% to -$1.9 million in 2025.
• Per Business Quant, the three latest RGNX Change in Account Payables figures stand at -$1.9 million (Q4 2025), $694000.0 (Q3 2025), and $2.5 million (Q2 2025).